These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31200828)

  • 1. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
    Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
    Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
    Goffin JR; Nicholas G; Mates M; Tu D; Chen E; Laurie SA; Juergens R; Robinson A; Goss G; Reaume M; Sun S; Christink K; Maize C; MacFarlan S; Sun X; Ritter H; Seymour L; Bradbury PA
    Invest New Drugs; 2019 Jun; 37(3):498-506. PubMed ID: 30317534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).
    Jänne PA; Mann H; Ghiorghiu D
    Clin Lung Cancer; 2016 Mar; 17(2):e1-4. PubMed ID: 26837474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
    Soria JC; Fülöp A; Maciel C; Fischer JR; Girotto G; Lago S; Smit E; Ostoros G; Eberhardt WEE; Lishkovska P; Lovick S; Mariani G; McKeown A; Kilgour E; Smith P; Bowen K; Kohlmann A; Carlile DJ; Jänne PA
    Ann Oncol; 2017 Dec; 28(12):3028-3036. PubMed ID: 29045535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
    Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R
    Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
    Carter CA; Rajan A; Keen C; Szabo E; Khozin S; Thomas A; Brzezniak C; Guha U; Doyle LA; Steinberg SM; Xi L; Raffeld M; Tomita Y; Lee MJ; Lee S; Trepel JB; Reckamp KL; Koehler S; Gitlitz B; Salgia R; Gandara D; Vokes E; Giaccone G
    Ann Oncol; 2016 Apr; 27(4):693-9. PubMed ID: 26802155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
    Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
    Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
    Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
    Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
    Jänne PA; van den Heuvel MM; Barlesi F; Cobo M; Mazieres J; Crinò L; Orlov S; Blackhall F; Wolf J; Garrido P; Poltoratskiy A; Mariani G; Ghiorghiu D; Kilgour E; Smith P; Kohlmann A; Carlile DJ; Lawrence D; Bowen K; Vansteenkiste J
    JAMA; 2017 May; 317(18):1844-1853. PubMed ID: 28492898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
    Spigel DR; Shipley DL; Waterhouse DM; Jones SF; Ward PJ; Shih KC; Hemphill B; McCleod M; Whorf RC; Page RD; Stilwill J; Mekhail T; Jacobs C; Burris HA; Hainsworth JD
    Oncologist; 2019 Dec; 24(12):e1409-e1416. PubMed ID: 31420467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
    Jänne PA; Smith I; McWalter G; Mann H; Dougherty B; Walker J; Orr MC; Hodgson DR; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios CH; Franke FA; Crinò L; Smith P
    Br J Cancer; 2015 Jul; 113(2):199-203. PubMed ID: 26125448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
    Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
    Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
    Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
    Bradbury PA; Morris DG; Nicholas G; Tu D; Tehfe M; Goffin JR; Shepherd FA; Gregg RW; Rothenstein J; Lee C; Kuruvilla S; Keith BD; Torri V; Blais N; Hao D; Korpanty GJ; Goss G; Melosky BL; Mates M; Leighl N; Ayoub JP; Sederias J; Feilotter H; Seymour L; Laurie SA
    Lung Cancer; 2018 Jun; 120():142-148. PubMed ID: 29748010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
    Gerber DE; Socinski MA; Neal JW; Wakelee HA; Shirai K; Sequist LV; Rosovsky RP; Lilenbaum RC; Bastos BR; Huang C; Johnson ML; Hesketh PJ; Subramaniam DS; Dietrich MF; Chai F; Wang Y; Kazakin J; Schwartz B; Schiller JH; Brahmer JR; Kelly RJ
    Lung Cancer; 2018 Mar; 117():44-49. PubMed ID: 29496255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
    Platania M; Pasini F; Porcu L; Boeri M; Verderame F; Modena Y; Del Conte A; Nichetti F; Garassino MC; Martinetti A; Sottotetti E; Cavanna L; Vattemi E; Pozzessere D; Bertolini A; Irtelli L; Verri C; Sozzi G; Proto C; Pastorino U; Torri V; Fraccon AP; Spinnato F; Signorelli D; Lo Russo G; Tuzi A; Gallucci R; Cinieri S; Mencoboni M; Antonelli P; Giacomelli L; de Braud F
    Lung Cancer; 2019 Jun; 132():17-23. PubMed ID: 31097088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
    J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.